Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Continuing with our post-ASCO highlights presentation, we now turn to Dr. Joel Neal, Assistant Professor at Stanford Cancer Center, who covered several targeted therapy options that are still working their way through investigational work. There were several promising agents reported as potential treatments for lung cancer, but perhaps none was more exciting than anti-PD-1 immunotherapy that was described by Dr. Julie Brahmer in a podcast from a few months ago. She actually led and presented the work on anti-PD-1 in lung cancer at ASCO, but she wasn't able to share her exciting early results prior to ASCO. Dr. Neal provides both some background and a summary of the results that were so encouraging to the lung cancer community.
Below you'll find the video and audio versions of the podcast, along with the transcript and figures.
Dr. Neal ASCO 2012 LC Highlights Anti-PD-1 Audio Podcast
Dr. Neal ASCO 2012 LC Highlights Anti-PD-1 Figs
Dr. Neal ASCO 2012 LC Highlights Anti-PD-1 Transcript
So how encouraged are you by these results?
We'll continue with other novel therapies presented at ASCO 2012 and summarized by Dr. Neal in our next podcast.
In the meantime,
Please feel free to offer comments and raise questions in our
discussion forums.
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...
Hi Stan! So good to hear from you. I'm sorry for the late response. I too have been out of town with family and missed your post, probably because I was...
It is so good to hear from you! And I am so happy to hear that your holidays have been good and that you are doing well. It sounds like your...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components: